News | February 23, 2023
Research underscores Beyfortus’ potential to prevent RSV disease in infants
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
48-week data from MOMENTUM phase III clinical trial show momelotinib maintained total symptom response
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
Innovative TIMScore for dda-PASEF and dia-PASEF libraries, combined with TIMS DIA-NN identifies 9000 protein groups from 200 ng K562 lysate in just 35 min gradient
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
Former Interim CEO takes charge to drive strategic growth, strengthen clinical excellence, and advance patient-centric oncology innovation
New facility in Sector 51 offers advanced, affordable, and patient-centric dialysis services for NCR patients
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
Safety was equally impressive. ENV-294 was well tolerated
They also differentiated the innovator biologic Semaglutide molecule from newer synthetic or chemical generic versions entering the market
Subscribe To Our Newsletter & Stay Updated
